Gilead quarterly profit beats Street estimates, revenue up 5%
Adds analyst comment, share price, paragraphs 4-6
By Deena Beasley
Aug 8 (Reuters) -Gilead Sciences GILD.O on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings.
The Foster City, California-based company posted a quarterly profit of $2.01 per share excluding items, on revenue of $7 billion, up from $1.34 a share and revenue of $6.6 billion in the year-ago quarter.
Wall Street analysts had expected an adjusted profit of $1.60 per share on revenue of $6.72 billion, according to LSEG data.
It was a "mixed albeit solid quarter unlikely to dramatically change perceptions," RBC Capital Markets analyst Brian Abrahams said in a research note.
He said Gilead's solid tumor oncology franchise continues to face commercial and developmental challenges, but HIV remains steady and the success of long-acting agents has lifted sentiment.
Gilead shares, which rose 2% in regular Nasdaq trading on Thursday, were little changed at $75.60 after hours.
“It was a very strong quarter of commercial execution," CEO Daniel O'Day told Reuters in an interview, citing recent data showing that the company's long-acting injectable drug lenacapavir was more effective in preventing HIV infection in women compared to a daily pill.
He said the company also looks forward to a potential U.S. launch of seladelpar, a liver drug acquired with Gilead's purchase earlier this year of CymaBay, for primary biliary cholangitis. The U.S. Food and Drug Administration is slated to decide on the drug's approval by next Wednesday.
Quarterly sales of HIV drug Biktarvy rose 8% to $3.2 billion, which was in line with analysts' estimates. Sales of its COVID-19 treatment Veklury fell 16% to $214 million, but still came in well above Wall Street expectations of $190 million.
Oncology sales rose 15% to $841 million, while sales of liver disease drugs rose 17% to $832 million.
For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but raised its adjusted profit estimate to $3.60 to $3.90 a share from a previous $3.45 to $3.85 a share.
Analysts have projected 2024 earnings per share of $3.75 on revenue of $27.58 billion.
Reporting By Deena Beasley
Editing by Bill Berkrot
免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。